NYSE:RCUS Arcus Biosciences (RCUS) Stock Price, News & Analysis → Top Project Outperforms BTC in 2023… (From Crypto 101 Media) (Ad) Free RCUS Stock Alerts $18.90 +0.69 (+3.79%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$18.18▼$19.1150-Day Range$14.82▼$20.1852-Week Range$12.95▼$25.47Volume744,391 shsAverage Volume883,880 shsMarket Capitalization$1.72 billionP/E RatioN/ADividend YieldN/APrice Target$41.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Arcus Biosciences alerts: Email Address Arcus Biosciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside118.3% Upside$41.25 Price TargetShort InterestBearish16.86% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.48Based on 9 Articles This WeekInsider TradingAcquiring Shares$320 M Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.80 out of 5 starsMedical Sector554th out of 938 stocksPharmaceutical Preparations Industry253rd out of 425 stocks 3.4 Analyst's Opinion Consensus RatingArcus Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $41.25, Arcus Biosciences has a forecasted upside of 118.3% from its current price of $18.90.Amount of Analyst CoverageArcus Biosciences has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted16.86% of the float of Arcus Biosciences has been sold short.Short Interest Ratio / Days to CoverArcus Biosciences has a short interest ratio ("days to cover") of 9.3.Change versus previous monthShort interest in Arcus Biosciences has recently increased by 3.91%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldArcus Biosciences does not currently pay a dividend.Dividend GrowthArcus Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RCUS. Previous Next 1.9 News and Social Media Coverage News SentimentArcus Biosciences has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Arcus Biosciences this week, compared to 3 articles on an average week.Search InterestOnly 11 people have searched for RCUS on MarketBeat in the last 30 days. This is a decrease of -48% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Arcus Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arcus Biosciences insiders have bought 32,149.38% more of their company's stock than they have sold. Specifically, they have bought $319,999,995.00 in company stock and sold $992,267.00 in company stock.Percentage Held by Insiders13.80% of the stock of Arcus Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions92.89% of the stock of Arcus Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Arcus Biosciences are expected to remain at ($3.59) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcus Biosciences is -4.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcus Biosciences is -4.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcus Biosciences has a P/B Ratio of 3.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaTop Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.Just click here for instant access to the #1 Coin for 2024. About Arcus Biosciences Stock (NYSE:RCUS)Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.Read More RCUS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RCUS Stock News HeadlinesMarch 21, 2024 | insidertrades.comInsider Selling: Arcus Biosciences, Inc. (NYSE:RCUS) COO Sells 13,449 Shares of StockMarch 27, 2024 | americanbankingnews.comArcus Biosciences, Inc. (NYSE:RCUS) Receives Average Rating of "Moderate Buy" from BrokeragesMarch 28, 2024 | Crypto 101 Media (Ad)Top Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.March 26, 2024 | businesswire.comArcus Biosciences Announces New Employment Inducement GrantsMarch 26, 2024 | americanbankingnews.comArcus Biosciences (NYSE:RCUS) Given Buy Rating at Truist FinancialMarch 25, 2024 | markets.businessinsider.comNavigating 5 Analyst Ratings For Arcus BiosciencesMarch 22, 2024 | investing.comArcus Biosciences COO sells over $240k in company stockMarch 22, 2024 | americanbankingnews.comJennifer Jarrett Sells 13,449 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) StockMarch 28, 2024 | Crypto 101 Media (Ad)Top Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.March 20, 2024 | finance.yahoo.comInsider Sell: COO Jennifer Jarrett Sells 13,449 Shares of Arcus Biosciences Inc (RCUS)March 11, 2024 | businesswire.comArcus Biosciences Announces New Employment Inducement GrantsFebruary 29, 2024 | finance.yahoo.comInsider Sell: COO Jennifer Jarrett Sells 58,625 Shares of Arcus Biosciences Inc (RCUS)February 28, 2024 | businesswire.comArcus Biosciences to Participate in Two Upcoming Investor ConferencesFebruary 27, 2024 | businesswire.comArcus Biosciences Announces New Employment Inducement GrantsFebruary 26, 2024 | markets.businessinsider.comEvaluating Arcus Biosciences’ Casdatifan Potential and Strategic Position in RCC Treatment LandscapeFebruary 22, 2024 | msn.comGilead downgraded at Truist on cancer strategyFebruary 22, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Arcus Biosciences (RCUS), Ionis Pharmaceuticals (IONS) and Icon (ICLR)February 22, 2024 | finance.yahoo.comArcus Biosciences, Inc. (NYSE:RCUS) Q4 2023 Earnings Call TranscriptFebruary 22, 2024 | seekingalpha.comArcus Biosciences: Trading At Large Discount To Recent Gilead InvestmentFebruary 21, 2024 | msn.comArcus Biosciences GAAP EPS of -$1.08 misses by $0.06, revenue of $31M beats by $2.7MFebruary 21, 2024 | finance.yahoo.comArcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline UpdateFebruary 21, 2024 | businesswire.comArcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline UpdateFebruary 18, 2024 | finance.yahoo.comRCUS Mar 2024 30.000 callFebruary 18, 2024 | finance.yahoo.comRCUS Mar 2024 20.000 putFebruary 17, 2024 | ca.finance.yahoo.comRCUS Mar 2024 10.000 callFebruary 17, 2024 | ca.finance.yahoo.comRCUS Mar 2024 12.500 callFebruary 16, 2024 | finance.yahoo.comDTIL Mar 2024 2.500 putSee More Headlines Receive RCUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcus Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/21/2024Today3/28/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:RCUS CUSIPN/A CIK1724521 Webwww.arcusbio.com Phone(510) 694-6200FaxN/AEmployees577Year FoundedN/APrice Target and Rating Average Stock Price Target$41.25 High Stock Price Target$70.00 Low Stock Price Target$23.00 Potential Upside/Downside+118.3%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($4.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-307,000,000.00 Net Margins-262.39% Pretax Margin-257.27% Return on Equity-57.17% Return on Assets-25.80% Debt Debt-to-Equity RatioN/A Current Ratio4.52 Quick Ratio4.52 Sales & Book Value Annual Sales$117 million Price / Sales14.68 Cash FlowN/A Price / Cash FlowN/A Book Value$6.17 per share Price / Book3.06Miscellaneous Outstanding Shares90,860,000Free Float78,326,000Market Cap$1.72 billion OptionableOptionable Beta0.82 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Terry J. Rosen Ph.D. (Age 64)Co-Founder, Chairman & CEO Comp: $756.11kDr. Juan Carlos Jaen Ph.D. (Age 66)Co- Founder & President Comp: $931.14kMr. Robert C. Goeltz II (Age 51)Principal Financial Officer & CFO Comp: $745.29kMs. Jennifer A. Jarrett M.B.A. (Age 53)Chief Operating Officer Comp: $925.29kDr. Dimitry S.A. Nuyten M.D. (Age 48)Ph.D., Chief Medical Officer Comp: $700.34kDr. K. Christopher Garcia Ph.D.Co-Founder & Member of Scientific Advisory BoardMr. Alexander Azoy (Age 48)VP of Finance & Principal Accounting Officer Dr. Jonathan Yingling Ph.D. (Age 55)Chief Scientific Officer Ms. Katherine BockVice President of Investor Relations & Corporate StrategyMs. Carolyn C. Tang J.D. (Age 45)General Counsel & Corporate Secretary Comp: $603.2kMore ExecutivesKey CompetitorsKura OncologyNASDAQ:KURAAvadel PharmaceuticalsNASDAQ:AVDLANI PharmaceuticalsNASDAQ:ANIPDisc MedicineNASDAQ:IRONZai LabNASDAQ:ZLABView All CompetitorsInsiders & InstitutionsPNC Financial Services Group Inc.Sold 2,394 shares on 3/22/2024Ownership: 0.002%Jennifer JarrettSold 13,449 sharesTotal: $241,006.08 ($17.92/share)Vanguard Group Inc.Bought 186,898 shares on 3/11/2024Ownership: 5.152%Goldman Sachs Group Inc.Bought 4,083 shares on 3/1/2024Ownership: 0.652%Juan C JaenSold 3,900 sharesTotal: $78,234.00 ($20.06/share)View All Insider TransactionsView All Institutional Transactions RCUS Stock Analysis - Frequently Asked Questions Should I buy or sell Arcus Biosciences stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RCUS shares. View RCUS analyst ratings or view top-rated stocks. What is Arcus Biosciences' stock price target for 2024? 8 brokers have issued 12 month target prices for Arcus Biosciences' shares. Their RCUS share price targets range from $23.00 to $70.00. On average, they anticipate the company's stock price to reach $41.25 in the next year. This suggests a possible upside of 118.3% from the stock's current price. View analysts price targets for RCUS or view top-rated stocks among Wall Street analysts. How have RCUS shares performed in 2024? Arcus Biosciences' stock was trading at $19.10 at the beginning of the year. Since then, RCUS shares have decreased by 1.0% and is now trading at $18.90. View the best growth stocks for 2024 here. When is Arcus Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our RCUS earnings forecast. How were Arcus Biosciences' earnings last quarter? Arcus Biosciences, Inc. (NYSE:RCUS) posted its quarterly earnings results on Wednesday, February, 21st. The company reported ($1.08) EPS for the quarter, beating the consensus estimate of ($1.09) by $0.01. The firm had revenue of $31 million for the quarter, compared to analysts' expectations of $28.30 million. Arcus Biosciences had a negative net margin of 262.39% and a negative trailing twelve-month return on equity of 57.17%. The firm's quarterly revenue was down 8.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.93) earnings per share. What ETFs hold Arcus Biosciences' stock? ETFs with the largest weight of Arcus Biosciences (NYSE:RCUS) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), Range Cancer Therapeutics ETF (CNCR), ALPS Medical Breakthroughs ETF (SBIO) and Invesco S&P SmallCap Health Care ETF (PSCH).Virtus LifeSci Biotech Clinical Trials ETF (BBC). What is Terry Rosen, Ph.D.'s approval rating as Arcus Biosciences' CEO? 4 employees have rated Arcus Biosciences Chief Executive Officer Terry Rosen, Ph.D. on Glassdoor.com. Terry Rosen, Ph.D. has an approval rating of 100% among the company's employees. This puts Terry Rosen, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Arcus Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arcus Biosciences investors own include Horizon Therapeutics Public (HZNP), BioDelivery Sciences International (BDSI), Pfizer (PFE), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), CRISPR Therapeutics (CRSP), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Agile Therapeutics (AGRX) and Advanced Micro Devices (AMD). When did Arcus Biosciences IPO? Arcus Biosciences (RCUS) raised $99 million in an IPO on Thursday, March 15th 2018. The company issued 7,100,000 shares at $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO. Who are Arcus Biosciences' major shareholders? Arcus Biosciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (6.25%), Vanguard Group Inc. (5.15%), Octagon Capital Advisors LP (2.50%), Dimensional Fund Advisors LP (2.13%), Decheng Capital LLC (1.16%) and Point72 Asset Management L.P. (1.03%). Insiders that own company stock include Alexander Azoy, Carolyn C Tang, Carolyn C Tang, Gilead Sciences, Inc, Jennifer Jarrett, Juan C Jaen, Kathryn E Falberg, Robert C Goeltz II, Terry J Rosen, William Grossman and Yasunori Kaneko. View institutional ownership trends. How do I buy shares of Arcus Biosciences? Shares of RCUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:RCUS) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill Publishing“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryFed launches fourth dollar overhaulStansberry ResearchThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyInvestors Alert: The Next Big Thing in Weight LossBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.